anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a rhodiola root buccal tablet, which is prepared from rhodiola root extract dry powder, mannitol, dextrin, CMC-NA, a sweetening agent, micropowder silica gel, magnesium stearate, menthol and lemon extract. The invention further provides a method for preparing the rhodiola root buccal tablet. The buccal tablet provided by the invention is health food prepared from the main raw material of rhodiola root extract dry powder. Proven through animal meal function test, the buccal tablet has the health protection functions of easing strain of human bodies, and improving tolerance to anoxia. The buccal tablet is prepared by adopting the advanced process, and has the special aroma of rhodiola root and moderate aftertaste, which is sweet and tasty without bitter. The tablet can be conveniently administrated by the young, the middle-aged and the elderly.
BACKGROUND: Amyloidosis is a rare condition characterized by the abnormal deposition of amyloid proteins in various tissues and organs. While systemic amyloidosis has been well-documented, amyloid deposition in extraocular muscles is an exceptionally rare occurrence, with only 35 reported cases. This case report sheds light on the importance of considering amyloidosis in the differential diagnosis of patients presenting with proptosis and diplopia, which are often associated with thyroid eye disease.
CASE PRESENTATION: A woman in her twenties sought medical attention due to a complaint of diplopia. Her ocular examination revealed almost normal findings except for exotropia and proptosis. Orbital magnetic resonance imaging displayed fusiform enlargement of nearly all eye muscles, a presentation typically observed in thyroid eye disease. However, despite corticosteroid therapy, her symptoms showed no improvement. Given the unusual lack of response to conventional treatment, and inhomogeneous enhancement of the muscle, an extraocular muscle biopsy was conducted. This biopsy yielded a unique finding-amyloid deposition within the muscle tissue. This discovery was particularly intriguing due to the extreme rarity of amyloidosis affecting extraocular muscles, with fewer than three dozen documented cases worldwide.
CONCLUSION: This unique case underscores the critical need for a comprehensive approach to diagnosing patients with proptosis and diplopia. While these symptoms are commonly attributed to thyroid eye disease, it is essential to consider alternative diagnoses such as amyloidosis, especially when standard treatments fail to yield results. The discovery of amyloid deposition in the extraocular muscles, although exceedingly rare, emphasizes the significance of a thorough differential diagnosis. In conclusion, this case report highlights the importance of vigilance in clinical practice, encouraging ophthalmologists to explore less common diagnostic possibilities when faced with challenging cases. Further research and clinical investigation are warranted to better understand the mechanisms and potential treatments for amyloidosis affecting the extraocular muscles.
Neurocritically ill patients frequently exhibit coma, gastroparesis, and intense catabolism, leading to an increased risk of malnutrition. The Global Leadership Initiative on Malnutrition (GLIM) criteria for the diagnosis of malnutrition was created to achieve a consistent malnutrition diagnosis across diverse populations. This study aimed to validate the concurrent and predictive validity of GLIM criteria in patients with neurocritical illnesses. A total of 135 participants were followed from admission to the neurocritical unit (NCU) until discharge. Comparing GLIM criteria to the Subjective Global Assessment (SGA), sensitivity was 0.95 and specificity was 0.69. Predictive validity of GLIM criteria was assessed using a composite adverse clinical outcome, comprising mortality and various major complications. Adjusted hazard ratios for moderate and severe malnutrition were 2.86 (95% CI 1.45-5.67) and 3.88 (95% CI 1.51-9.94), respectively. Changes in indicators of nutritional status, including skeletal muscle mass and abdominal fat mass, within 7 days of admission were obtained for 61 participants to validate the predictive capability of the GLIM criteria for the patients' response of standardized nutritional support. The GLIM criteria have a statistically significant predictive validity on changes in rectus femoris muscle thickness and midarm muscle circumference. In conclusion, the GLIM criteria demonstrate high sensitivity for diagnosing malnutrition in neurocritically ill patients and exhibit good predictive validity.
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.

Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology.

Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.

Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to ≤ Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis [see Dosage and Administration (2.4)]. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.
PURPOSE:To provide a humectant containing a water-soluble polyhydric alcohol and a monoacyl phospholipid, free from stickiness in use, exhibiting high and lasting moisture-keeping effect and useful as a component of cosmetic or drug. CONSTITUTION:The objective agent is produced by using (A) a water-soluble polyhydric alcohol (e.g. glycerol) and (B) a compound of formula I or formula II (R is group of formula III or formula IV; X is group of formula V, formula VI or formula VII) as essential components and, as necessary, compounding (C) a component such as sodium pyrrolidonecarboxylate, an amino acid, a water- soluble polymer or collagen and further (D) a perfume, a colorant, a preservative, a drug, an alcohol, etc. The ratio of the water-soluble polyhydric alcohol to the monoacyl phospholipid is (1000-20):1. The compound of formula I or formula II is e.g. 1-palmitoyl-3-glycerylphosphorylcholine.
A headset, configured to be attached to a human head, includes an accelerometer providing a signal indicative of head acceleration due to blood flow through the brain. An analyzer evaluates a plurality of samples indicative of acceleration over time where each sample corresponds to the head movement resulting from a cardiac contraction. The analyzer identifies brain conditions at least partially based on a level of chaos of the plurality samples. The algorithm applied by the analyzer is partially formulated based on clinical data and examination of a plurality of subjects. In one example, the plurality of samples evaluated by the analyzer are indicative of the head accelerometer only in a single axis. In some situations, the analyzer identifies brain conditions further based on contemporaneous neurological examination of the subject.
PD-1/PD-L1 inhibitors have achieved surprising results in lung cancer treatment and have been approved by the FDA for the treatment of different types of lung cancer. Their overall toxicity is lower than that of standard chemotherapy, but a number of immune-related adverse events have been reported clinically. Liver injury is one of the leading causes of death from adverse events due to PD-1/PD-L1 inhibitors. The occurrence of immune-related liver damage has an important impact on the tumor treatment and prognosis of patients. Most of the current domestic and international studies focus on the overall description and study of PD-1/PD-L1 antibody-related adverse events, and there is no definitive description of the risk factors for the development of immune-related liver injury in lung cancer patients. The aim of this project is to review the clinical data of lung cancer patients treated with PD-1/PD-L1 inhibitors from 2020.01 to 2024.06, to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury, and to take measures to prevent the occurrence of fatal immune liver injury, which is of great significance to the immunotherapy of clinical tumor patients. It is of great significance to the immunotherapy of clinical tumor patients.
The AMMO digital therapeutic (DTx) will be a novel intervention for PTH following concussive TBI, therefore this project is a pilot trial designed to test this new treatment. This pilot is a single-blind, randomized, controlled, interventional trial of current and former military personnel along with civilians with a history of concussive TBI and current PTH. The pilot trial will be conducted via online portal accessible by smartphone, tablet, or computer with remote interaction between participants and study staff. The pilot trial will include up to 100 participants randomized to either the active intervention or a comparison condition at a 1:1 ratio, and will provide preliminary data to determine the sample size of a future full clinical trial. Participants will complete a 12 week intervention period followed by a follow-up assessment 4 weeks after intervention is complete. Participants randomized to the comparison group will be provided access to the open label after end of 16 week follow-up.

In addition, updates to the DTx to improve usability and acceptability will be made if necessary based on feedback from the pilot trial, then applied to the final DTx used in a future, larger, clinical trial.
INTRODUCTION: Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with intensely pruritic, hyperkeratotic nodules. The pathophysiology underlying PN is not entirely clear, making treatment challenging. Patients often require a multimodal approach, although many of the available therapies have low efficacy or adverse effects.
AREAS COVERED: In this review, we discuss the use of nemolizumab for the treatment of PN in adults. Nemolizumab is a biological therapy that reduces type 2 cytokines and the neuroimmune response implicated in the pathophysiology of PN. It also helps maintain skin barrier integrity, which may be damaged during the vicious itch-scratch cycle. Nemolizumab has demonstrated great efficacy in improving itch and clearing lesions in recent clinical trials with respectable tolerance.
EXPERT OPINION: Nemolizumab is a promising drug for PN that seems comparable to the recently approved dupilumab in terms of its therapeutic effect and excellent safety profile, although nemolizumab may work more rapidly on itch. JAK inhibitors are also emerging as competitors of biologics for PN, however, their safety profile in this population may differ. Trials evaluating these drugs are needed to assess which is preferable. Additional data on the durability and longevity of nemolizumab for PN treatment is highly anticipated.
The usual recommended starting dose is 0.07 mg/kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients (see CLINICAL PHARMACOLOGY, PharmacokineticsandMetabolism and Pharmacodynamics and Clinical Effects).

Lisinopril tablets USP are not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73 m2 (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism and Pharmacodynamics and Clinical Effects and PRECAUTIONS).

### Preparation of Suspension (for 200 mL of a 1 mg/mL Suspension)

Add 10 mL of Purified Water USP to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of lisinopril tablets USP and shake for at least one minute. Add 30 mL of Bicitra® diluent and 160 mL of Ora-Sweet SF™ to the concentrate in the PET bottle and gently shake for several seconds to disperse the ingredients. The suspension should be stored at or below 25°C (77°F) and can be stored for up to four weeks. Shake the suspension before each use.
There are provided cleavable surfactants of formula: [in which R' and R, which may be identical or different, represent a hydrogen atom or a linear or branched, saturated or unsaturated alkyl radical, the sum of the carbon atoms of R' and R being between 5 and 42], and derivatives thereof of formulae IIa, IIb. IIIa and IIIb which are obtainable by alkaline hydrolysis or amidation respectively. The surfactants of formulae la and Ib are prepared from glucono-1 (5)-lactone and a compound of formula R-CO-R' in the presence of an acid catalyst, R and R' being as defined above. in which: each of R' and R, is as defined above; Z<SP>n+</SP> represents a cation of an alkali metal or alkaline-earth metal, or a quaternary ammonium of formula: in which each of R 2 ' R 3 ' R 4  and R 5 , which may be the same or different, represents an alkyl or hydroxyalkyl radical containing 1 to 18 carbon atoms, an alkylaryl radical containing 7 to 18 carbon atoms or a basic amino acid residue; and n is the valency of the cation. in which: each of R' and R, is as defined above; and R 1  represents a linear or branched mono- or polyhydroxyalkyl radical containing 2 to 12 carbon atoms. The surfactants are useful in particular in emulsion polymerization, in cosmetic compositions, as antistatic agents for the treatment of textiles, wetting agents for the treatment of leathers and metals, and emulsifiers in the petroleum field.
The method for the intensive therapy in the acute period of the severe craniocerebral trauma consists in assessing the parameters of red blood cells, the state of the endothelium, the hemostasis, the acute mediatosis, and the state of immune system. Then, based on the results of such an assessment, the additional substances are prescribed for supplementing the basic therapy. In particular, L-lysine escinate is given as the tonic, immunocorrecting, hypoglycemic, and analgesic substance. Sorbilact or reosorbilact is given as desaggregant, detoxifying, osmodiuretic, antishock, rheologic, and acidosis-correcting agent dependent on the osmolarity of blood plasma. Perfluorane is given intravenously at a dose of 3 ml/kg at the rate of 30-60 drops per minute within three days of the acute period with the concomitant oxygen inhalation under the control of blood pressure. L-lysine escinate is administered in a volume of 10 ml twice a day for 7 days until the stable therapeutic effect is attained. Sorbilact or reosorbilact is used in a volume of 200 ml twice a day for 7 days.
The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
The purpose of this study is to strengthen our ability to understand the long-term effects of food immunotherapy on the immune system and how it may induce tolerance to foods that participants were once allergic to. Investigators hope to determine tools and immunologic parameters that can help predict sustained desensitization and tolerance to food allergens following food immunotherapy. By evaluating the in-depth characteristics of allergy antibody populations and other immunologic parameters and comparing them to clinical disease, the investigators may uncover a more sound way to diagnose, follow and treat food allergic disease over time. Investigators will follow up with participants who underwent immunotherapy to food allergens as volunteers in clinical trials at the Sean N. Parker Center and assess whether they experience sustained desensitization to these foods in the long-term. Investigators will investigate the properties of the participants' immune cells and how they are affected over time by the ingestion of these food allergens. Investigators will follow the significance of different dosing regimens in terms of achieving tolerance. Differences in immune cell characteristics and other biological parameters may help predict the nature of a participant's tolerance to the food allergens and may help in the development of tools to determine permanent tolerance.
Participants in the active control condition listened to a 15-minute story. The audio track of the control condition is embedded in the Qualtrics survey.
An apparatus, system, and method for monitoring a person suffering from a chronic medical condition predicts and assesses physiological changes which could affect the care of that subject. Examples of such chronic diseases include (but are not limited to) heart failure, chronic obstructive pulmonary disease, asthma, and diabetes. Monitoring includes measurements of respiratory movements, which can then be analyzed for evidence of changes in respiratory rate, or for events such as hypopneas, apneas and periodic breathing. Monitoring may be augmented by the measurement of nocturnal heart rate in conjunction with respiratory monitoring. Additional physiological measurements can also be taken such as subjective symptom data, blood pressure, blood oxygen levels, and various molecular markers. Embodiments for detection of respiratory patterns and heart rate are disclosed, together with exemplar implementations of decision processes based on these measurements.
The invention relates to a medicine for treating intestinal obstruction, especially to a traditional Chinese medicine composition for treating simple intestinal obstruction. According to the traditional Chinese medicine composition, Angelica sinensis is added to achieve the effects of moistening dryness and promoting blood circulation to remove blood stasis, has a curative effect of facilitating bowel movement by purgation on simple intestinal obstruction and accords with the therapeutic principle of purging away the obstruction and facilitating bowel movement by purgation. No obstruction, no pain. With the addition of Angelica sinensis, symptoms of vomiting, abdominal distension and stomachache disappear. Angelica sinensis can tonify middle-Jiao and Qi and can partly eliminate deficiency-cold in spleen and stomach that is caused by rheum officinale and folium sennae. By adding codonopsis pilosula, walnut kernel, propolis and honey, the effect of moistening dryness and facilitating bowel movement by purgation is further enhanced. Meanwhile, codonopsis pilosula can tonify middle-Jiao and Qi and can partly eliminate deficiency-cold in spleen and stomach that is caused by rheum officinale and folium sennae. Propolis also can kill bacteria and raise body immunity. Honey also can adjust taste of the decoction. Thus, the prescription of the invention has effects of enhancing gastrointestinal tract propelling movement, can obviously increase intestinal volume, and also can promote return of early simple intussusception and release obstruction.
This will be a prospective, randomized, double blinded placebo-controlled study at Erlanger hospital. Eligible patients who provide consent will be randomized into one of two arms receiving continuous intra-peritoneal local anesthetic with 0.2% Ropivacaine or saline. After inclusion criteria are met and consents are obtained all patients will be sent home with a pain measurement, a pill diary to record the quantity of narcotic tablets taken, and a questionnaire nausea and vomiting symptoms.

After placement of the ON-Q pain pump the select-a-flow rate will be set to 6 mL/hr for all study participants. . All study participants will be provided with rescue pain medications as needed. If possible non-narcotic medications such as Tylenol and non-steroidal anti-inflammatory's will be utilized first. If pain persists narcotic medications will be provided. Oxycodone 5 mg will be utilized unless a patient reported allergy exists. All rescue narcotics utilized will be converted into morphine equivalents and documented. All patients will be discharged with Oxycodone 5 mg with 35 tablets which provides pain coverage for 7 days after surgery. In addition to Oxycodone all patients will be discharged with Sprix, a nasal non-steroidal anti-inflammatory medication, as well as Zofran and movantik, a medication for narcotic induced constipation. All patients will be instructed to administer Sprix by placing one puff into each nostril every 6 hours for a total of 5 days after surgery. They will further be instructed to take oral Tylenol 1000 mg every 6 hours for a total of 4 days after surgery. Assigned research personnel will contact all patients to obtain the results of their survey and pill dairy at 48 hours and one week after surgery. Patients will then present for a two-week post-operative visit where study personnel will complete data collection. All study participants who request a narcotic refill within 6 weeks of surgery will be documented.
The invention discloses the new use of garlic oil, namely the application of the garlic oil in preparing the medicaments used for resist acute alcoholic fatty liver. 50 to 200 mg of garlic oil is contained in the medicaments resisting acute alcoholic fatty liver caused by alcohol of 4.8g/kg.bw per kilogram of body. The garlic oil is taken orally, and is taken two hours prior to drinking. Before the garlic oil is taken, the garlic oil can be diluted with corn oil. Proven through experiments on mice, the garlic oil can significantly reduce the liver index, sera TG, liver TG, and inhibit liver MDA l from rising caused by ethano, and can increase the content of GSH in the liver, which has the function of resisting acute alcoholic fatty liver. The garlic oil can be used for preparing medicaments for resisting acute alcoholic fatty liver, and establishes a new application way for preventing alcoholic hepatopathy.
A phytotherapeutic composition comprises herb extracts of Allium sativum, Eleutherococcus senticosus, Juglans regia, Echinacea purpurea, Viola tricolor, Uncaria tomentosa, and Carduus marianus. The phytotherapeutic composition has a broad area of use as a health product. The product furthers the general feeling of well being, increases stress tolerance, stimulates specific and aspecific immunity and harmonises vegetative functioning. In a prophylactic context it is recommended that the phytotherapeutic composition according to the invention be used when there is still some capacity left for recovery. This means administration before an infection has taken place or during the preliminary phase of an infectious process. The phytotherapeutic composition accelerates recovery after illness by furthering the recovery of the connective tissue and fighting oedema.
This is a cross-sectional (observations or measurements made at a single point in time, usually at participant enrollment), multi-center (conducted in more than one center), and comparative study of topiramate monotherapy in female participants with epilepsy. Female participants must have received either topiramate, carbamazepine, or valproic acid monotherapy for more than one year for the treatment of epilepsy. Blood samples will be obtained from fasting participants to investigate the effect of study drug on the bone and mineral metabolism markers, and bone density compared to healthy participants and comparative group (carbamazepine and valproic acid monotherapy). Bone mineral density will be measured from the participants' lumbar spine or femur. A survey of food intake and physical activity for the participants will be performed using a standardized validated detailed questionnaire. The post-study visit (or follow up phone contact) will be performed for the occurrence of serious adverse events (SAE) for safety evaluation. Participants' safety will be monitored throughout the study.